Astellas-owned Xyphos offers more than $800M for Kelonia's in vivo delivery know-how

Just because cell therapy’s use in autoimmune diseases is now in vogue does not mean applications in cancer have evaporated.

Astellas is proving that point, with its subsidiary Xyphos linking arms with Kelonia in a research and licensing deal worth north of $800 million, according to an announcement Thursday evening.